Use and outcomes of epoetin alfa and darbepoetin alfa for anemic cancer patients in outpatient community practice settings.

被引：1
|
作者：
Fahrbach, KR
Frame, D
Sercus, B
Schenkel, B
机构：
[1] Metaworks Inc, Res & Stat, Medford, MA USA
[2] Johnson & Johnson Pharmaceut Serv LLC, Hlth Econ & Pricing, Raritan, NJ USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.5588.5588
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5588
引用
收藏
页码：485B / 486B
页数：2
相关论文
共 50 条
  • [31] HEMATOLOGIC OUTCOMES AND DOSING PATTERNS IN ANEMIC PATIENTS WITH PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) SWITCHING FROM DARBEPOETIN ALFA (DARB) TO EPOETIN ALFA (EPO)
    Hura, Claudia
    Jackson, James
    Lunacsek, Orsolya
    Bailey, Robert A.
    McKenzie, R. Scott
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 55 (04) : A65 - A65
  • [32] Propensity score matched evaluation of epoetin alfa and darbepoetin alfa utilization in patients with cancer receiving chemotherapy.
    Bailey, R. A.
    Tunceli, O.
    Singer, J.
    Stephenson, J. J.
    Senbetta, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Darbepoetin alfa is cost effective compared to epoetin alfa for treatment of anemia in cancer patients receiving chemotherapy.
    Glaspy, JA
    Tchekmedyian, NS
    Gupta, S
    BLOOD, 2002, 100 (11) : 874A - 875A
  • [34] Hemoglobin responses following darbepoetin alfa (Aranesp®) vs. epoetin alfa (Procrit®) administration in anemic chronic kidney disease (CKD) patients
    Sarac, E
    Veres, Z
    Schuler, E
    Tallum, S
    Gemmel, DJ
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V264 - V264
  • [35] Efficacy of Epoetin alfa in community practice of oncology
    Spiridonidis, CH
    Brinkmann, K
    Gore, K
    Tannous, RE
    Gupta, S
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 287 - 288
  • [36] Prediction of treatment response in anemic patients with cancer using darbepoetin alfa (DARB)
    Camara, O.
    Hartmann, M.
    Egbe, A.
    Koch, I.
    Runnebaum, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN CANCER INPATIENTS RECEIVING CHEMOTHERAPY
    Vekeman, F.
    Bailey, R.
    Lafeuille, M. H.
    McKenzie, R. S.
    Herrera, A. D.
    Lefebvre, P.
    VALUE IN HEALTH, 2009, 12 (03) : A40 - A41
  • [38] HEMATOPOIETIC RESPONSE IN ANEMIC LUNG CANCER PATIENTS RECEIVING WEEKLY DARBEPOETIN ALFA
    Migliorino, Maria Rita
    De Petris, Luigi
    Martelli, Olga
    Mancuso, Andrea
    Di Salvia, Roberto
    De Marinis, Filippo
    ANNALS OF ONCOLOGY, 2004, 15 : 118 - 118
  • [39] BENEFITS OF EPOETIN ALFA THERAPY IN ANEMIC CANCER-PATIENTS RECEIVING CHEMOTHERAPY
    HENRY, DH
    ABELS, R
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (09) : 2473 - 2474
  • [40] Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy
    Waltzman, R
    Croot, C
    Justice, GR
    Fesen, MR
    Charu, V
    Williams, D
    ONCOLOGIST, 2005, 10 (08): : 642 - 650
12345